Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7144293 | 0.91 | SCN3A (0.56) | ALDH1A1HTTKMT2AMEN1GAA | |
| SCHEMBL7144288 | 0.91 | SCN3A (0.56) | ALDH1A1HTTKMT2AMEN1GAA | |
| Hydrochloric Acid SCHEMBL195248 | 0.90 | SCN3A (0.55) | ALDH1A1HTTKMT2AMEN1GAA | |
| SCHEMBL5901234 | 0.87 | HTT (0.61) | ALDH1A1HTTKMT2AMEN1GAA | |
| SCHEMBL11058260 | 0.85 | ALDH1A1 (0.58) | ALDH1A1HTTKMT2AMEN1GAA | |
| SCHEMBL9493215 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HTTKMT2AMEN1GAA | |
| SCHEMBL9494469 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HTTKMT2AMEN1GAA | |
| SCHEMBL9492819 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HTTKMT2AMEN1GAA | |
| SCHEMBL8249322 | 0.83 | ALDH1A1 (0.57) | ALDH1A1HTTKMT2AMEN1GAA | |
| Hydrochloric Acid SCHEMBL9653456 | 0.82 | ALDH1A1 (0.60) | ALDH1A1HTTKMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678121-A4 | TAO KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1678121-A2 | TAO KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2005040355-A2 | TAO KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-05-06 | — | — | WO | claimed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | TAOK1, TAOK3, MAP3K6 | ALDH1A1 4424/4885HTT 4318/4885KMT2A 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.